Agenus Inc. (AGEN) shares surged 5.03% in after-hours on Thursday, September 16, 2021, and closed the daily trading at $5.85. Even in the regular trading session on Thursday, AGEN’s stock gained 3.63%. AGEN shares have risen 9.00% over the last 12 months, and they have moved down 14.83% in the past week. Over the past three months, the stock has gained 4.70%, while over the past six months, it has soared 77.96%.
AGEN data presentation at ESMO
On September 16, 2021, Agenus (AGEN) presented final results from the Bal/Zal combination study at the European Society for Medical Oncology (ESMO) Virtual Conference 2021 in an abstract titled Balstilimab (anti-PD-1) in combination with zalifrelimab (anti-CTLA-4).
In the Phase 2 trial, the objective response rate (ORR) in all 125 patients was 26%, with 9% of patients achieving a complete response, and 17% of patients achieving a partial response.
David O’Malley, MD. Will present the detailed results of the trial in a Mini Oral Session on September 19th from 11:35 – 11:40 am ET.
Partnership with Ginkgo
On September 10, 2021, Agenus (AGEN) launched its new subsidiary, SaponiQx, and its partnership with Ginkgo Bioworks, Inc. Ginkgo is enabling customers across industries to improve products and manufacturing processes, and to increase efficiency and sustainability, by making biology easier to engineer, after its recently announced business combination with Soaring Eagle Acquisition Corp.
AGEN participation in the recent investor conferences
Agenus (AGEN) recently participated at Baird 2021 Global Healthcare Conference which was held on September 15, 2021.
The company also participated at H.C. Wainwright 23rd Annual Global Investment Conference which was held on September 13, 2021.
AGEN balstilimab monotherapy results publication
On August 26, 2021, results from a global Phase 2 clinical study of Agenus Inc. (AGEN) balstilimab monotherapy in recurrent/metastatic cervical cancer were published online in the international peer-reviewed journal Gynecologic Oncology.
AGEN recent financial results announcement
On August 09, 2021, Agenus Inc. (AGEN), reported its financial results for the second quarter of 2021, which ended on June 30, 2021.
Q2 2021 financial highlights
- AGEN reported total revenue of $10.7 million for Q2 2021 compared to $26.95 million in Q2 2020.
- Research and development expenses were $45.5 million in Q2 2021 compared to$38.5 million in Q2 2020.
- It suffered a net loss of $84 million or net loss per share of $0.37 in Q2 2021 compared to a net loss of $48.3 million in or net loss per share of $0.28 Q2 2020.
- General and administrative expenses were $16.65 million in Q2 2021 compared to $14.2 million in Q2 2020.
- As of June 30, 2021, the company had a cash balance of $74 million as compared to $100 million on December 31, 2020.
Conclusion
The final results from the Bal/Zal combination study were the reason behind its top-notch performance on Thursday and we can expect it to continue its momentum on Friday as well.
